For Healthcare Professionals

A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

clipboard-pencil

About the study

This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Written informed consent obtained prior to any study-related procedure being performed;
  2. Age 18 years or older;
  3. Dose escalation(phase I): Patients with histologically or cytologically confirmed, advanced solid tumors (including lymphoma) which have progressed from standard therapy or for whom no standard therapy exists; Dose expansion(phase IIa ): Patients with histologically or cytologically confirmed, advanced NSCLC, ESCC, HNSCC which have progressed from standard therapy;
  4. Patients with life expectancy ≥3 months;
  5. Dose expansion(phase IIa ): patients have available archival tissue can be provided or willing to perform biopsy to provide fresh tumor tissue.
  6. Patients with other solid tumors must have at least one measurable lesion as defined by RECIST v1.1;Patients with Lymphomas must have at least one measurable lesion as defined by IWG 2007 criteria;
  7. Eastern Cooperative Oncology Group performance score 0 or 1;
  8. Patients who have sufficient baseline organ function.

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Patients with life-threatening autoimmune disease or with autoimmune disorder and who are on long-term steroid treatment;
  2. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO;
  3. Lymphoma with brain metastasis; Other solid tumors:Known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases;
  4. Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV)
  5. Patients who have any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the Investigator and Sponsor, could affect the patient's participation in the study
  6. Patients who have impaired cardiac function or clinically significant cardiac diseases
  7. Use of anti-cancer treatment drug ≤21 days prior to the first dose of JAB-3068.
  8. Use of an investigational drug during the past 30 days prior to the first dose of JAB-3068.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Non-small Cell Lung Cancer,Head and Neck Cancer,Esophageal Cancer,Other Metastatic Solid Tumors

Age (in years)

18+

Phase

Phase 1/Phase 2

Participants needed

120

Est. Completion Date

Sep 30, 2022

Treatment type

Interventional


Sponsor

Jacobio Pharmaceuticals Co., Ltd.

ClinicalTrials.gov identifier

NCT03565003

Study number

JAB-3068-02

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.